Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Balancing innovation and Common Sense In Oncology (CSO)

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Adjuvant radiotherapy has no benefit following radical prostatectomy

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer 

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC